Owing to their immunosuppressive properties, mesenchymal stromal cells (MSCs) obtained from bone marrow (BM-MSCs) or adipose tissue (ASCs) are considered a promising tool for cell therapy. However, important issues should be considered to ensure the reproducible production of efficient and safe clinical-grade MSCs. In particular, high expansion rate, associated with progressive senescence, was recently proposed as one of the parameters that could alter MSC functionality. In this study, we directly address the consequences of replicative senescence on BM-MSC and ASC immunomodulatory properties. We demonstrate that MSCs produced according to GMP procedures inhibit less efficiently T-cell, but not Natural Killer (NK)-and B-cell, proliferation after reaching senescence. Senescence-related loss-of-function is associated with a decreased indoleamine 2,3-dioxygenase (IDO) activity in response to inflammatory stimuli. In particular, although STAT-1-dependent IDO expression is transcriptionally induced at a similar level in senescent and nonsenescent MSCs, IDO protein is specifically degraded by the proteasome in senescent ASCs and BM-MSCs, a process that could be reversed by the MG132 proteasome inhibitor. These data encourage the use of appropriate quality controls focusing on immunosuppressive mechanisms before translating clinical-grade MSCs in the clinic. STEM CELLS 2017;35:1431-1436 
INTRODUCTION
Mesenchymal stromal cells (MSCs) are considered a promising tool for cell-based therapeutic strategies in the context of immune disorders and tissue regeneration [1] . The possibility to expand ex vivo high numbers of clinical-grade MSCs from bone marrow (BM-MSCs) or adipose tissue (ASCs) has paved the way for their therapeutic use. In agreement, more than 500 clinical trials evaluating MSC therapy in multiple clinical settings are registered (http://www.clinicaltrials.gov) and encouraging results have been reported in phase I/II trials [1, 2] . Interestingly, the efficacy of transplanted MSCs mainly relies on their paracrine ability to produce trophic factors, reduce inflammation, and dampen innate and adaptive immune response [3, 4] . The increasing use of MSCs and their classification by the Regulatory Authorities as strictly-controlled cellbased medicinal products has led to the development of large-scale standardized production processes [5, 6] . Understanding the main determinants that affect their immunomodulatory activity is crucial for the development of effective MSC strategies. For that purpose, the use of completely defined in vitro immunological assays is a prerequisite to limit uncontrolled technical variability [4, 7, 8] .
Besides interindividual variability, the scale of culture expansion and the related gradual entry into replicative senescence emerge as critical culture-related parameters that could influence clinical-grade MSC safety and clinical efficacy [9, 10] . In particular, late-passage MSCs were shown to be less effective than early-passage MSCs to control acute graftversus-host disease [11] . More generally, while academic groups essentially use a one-donor to one-recipient strategy with a minimal requirement for in vitro amplification, industry-driven trials are based on a one-donor to multiplerecipient strategy and involve MSCs with a high number of cumulative population doublings (PD) [9] . As senescence is observed in expanding human MSCs [10] , it can be hypothesized that long-term culture affects MSC clinical efficacy due to replicative senescence.
Previous analyses of the impact of senescence on MSC immunological properties led to opposite results in relation with the use of unstandardized MSC production processes, senescence induction, and immunological assays [12, 13] . In addition, whereas MSC priming by inflammatory stimuli is a prerequisite to trigger their suppressive function [14] , previous studies regarding MSC senescence only focused on resting MSCs. We investigate here the impact of replicative senescence, induced by long-term culture, on the ability of clinical grade BM-MSCs and ASCs to inhibit immune response. We highlight that senescent MSCs are less efficient than their nonsenescent counterpart to inhibit T-cell proliferation and identify the proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) immunosuppressive enzyme as a supportive mechanism.
MATERIALS AND METHODS
Complete Materials and Methods are available in the Supporting Information.
RESULTS AND DISCUSSION

Senescent MSCs Display Reduced Capacity to Inhibit T-Cell Proliferation
To analyze the impact of replicative senescence on immunological properties of MSCs, we maintained clinical-grade MSC batches in culture until senescence and compared paired senescent (SEN1) and nonsenescent (SEN2) cells from the same donors.
Reduced cell proliferation occurred after 25-35 cumulative PD for BM-MSCs and 35-45 cumulative PD for ASCs, and was associated with classical senescence features including increased cell size, b-galactosidase (b-gal) staining, and expression of p16INK4 as previously described [10] (Supporting Information Fig. S1A -S1C). To ensure data homogeneity, SEN1 and SEN2 MSC batches were defined by a combination of high cumulative PD/b-gal staining >25% versus low cumulative PD/b-gal staining <5% (Supporting Information Fig. S1D ) rather than by the passage number, a highly variable parameter in culture. We then compared the effect of SEN1 and SEN2 MSCs on activated purified immune effector cells instead of unfractionated peripheral blood mononuclear cells using robust and validated assays as proposed by the International Society for Cellular Therapy [8, 15] . Interestingly, SEN1 BM-MSCs and ASCs displayed a significantly decreased capacity to inhibit T-cell proliferation compared to their SEN2 counterpart regardless of the MSC-to-immune cell ratio although they retained their NK-cell inhibitory function ( Figure 1A , 1B and Supporting Information Fig. S2A ). SEN2 MSCs inhibited T-cell proliferation at a similar level upon transwell coculture (Supporting Information Fig. S2B ), showing that the mechanism involved was contact-independent. HGF and TGF-b were significantly upregulated at the mRNA level in ASCs and BM-MSCs during senescence in both resting and inflammatory context, ruling out that the loss of T-cell inhibitory properties of SEN1 MSCs was related to a decreased production of HGF and TGF-b1 soluble immunosuppressive molecules (Supporting Information Fig. S2C ). The capacity of human MSCs to inhibit T-cell, unlike NK-cell, proliferation in vitro was proposed to be dependent on their capacity to express functional IDO [4, 16] . We thus assessed IDO activity of SEN1 versus SEN2 MSCs after licensing by weak (20 IU/ml interferon (IFN)-g; Low IFN) versus strong (100 IU/ml IFN-g 11.5 ng/ml tumor necrosis factor (TNF)-a; Hi IFN 1TNF) inflammatory stimuli, as selected by the quantification of IDO mRNA ( Fig. 1C ). Of note, T cells produced similar to higher amounts of IFN-g and TNF-a when cocultured with SEN1 MSCs compared to SEN2 MSCs in agreement with the decreased T-cell suppressive activity of SEN1 MSCs, confirming that the lack of T-cell inhibition by SEN1 MSCs could not be attributed to a weaker inflammatory context (Supporting Information Fig. S2D ). Interestingly, whereas SEN1 and SEN2 MSCs responded to inflammatory cytokines by producing similar amount of IDO mRNA, SEN1 MSCs required a stronger priming than SEN2 to trigger a full IDO activity (Fig. 1D ). In agreement, priming of SEN1 MSCs by a strong inflammatory stimulus restored their capacity to inhibit T-cell proliferation (Fig. 1E ), even upon cell separation by a transwell (Supporting Information Fig. S2B ).
Overall these data provide evidences that senescent MSCs are specifically less suppressive toward T-cell immunity than nonsenescent MSCs, in association with a reduced IDO activity. Importantly, full senescence was obtained after only 4-9 passages for BM-MSCs versus 10-14 passages for ASCs (Supporting Information Fig. S1A ), indicating that senescence evaluation could be a valuable quality control, in particular for clinical-grade BM-MSCs. In addition, these data strengthen the potential interest of the priming of MSCs with inflammatory stimuli before their clinical use [17] .
IDO Activity Is Reduced in Senescent MSCs Through a Proteasome-Dependent Degradation Pathway
Given the discrepancy between IFN-g-dependent IDO transcription versus activity in SEN1 MSCs, we further explored the molecular mechanisms underlying IDO regulation during senescence. We first underlined, through inhibition by validated siRNA (Supporting Information Fig. S3 ) that STAT1 but not STAT3 was required for the induction of IDO transcription by IFN-g in MSCs ( Fig. 2A) , as described in other cell subsets [18, 19] . STAT1 signaling was retained during MSC senescence (Fig. 2B ), in agreement with the induction of similar levels of IDO mRNA by IFN-g in SEN1 versus SEN2 cells (Fig. 1C) . We next hypothesized that the decrease of IDO activity during MSC senescence could be due to a decrease of IDO protein stability. In fact, SEN1 MSCs contained less IDO protein than SEN2 MSCs after stimulation with weak inflammatory stimuli, a defect corrected by the use of a strong inflammatory priming (Fig. 2C ). Proteasome has been proposed to regulate IDO protein stability in various cell models [20, 21] . In addition, the proteasome is involved in the regulation of senescence that, in turn, alters the expression of proteasome pathway components [22] [23] [24] . We thus tested the MG132 reversible proteasome inhibitor on the inflammation-dependent expression of IDO in MSCs. Interestingly, MG132 specifically increased the amount of IDO protein and activity in SEN1 MSCs (Fig. 2D, 2E ), suggesting a crucial role for proteasome degradation pathway in the decrease of IDO activity, and subsequent reduction of immunosuppressive MSC properties during senescence. Identification of IDO-degrading factors and their inducers could provide new quality controls for clinical-grade MSC production as well as new potential targets to maintain IDO-dependent suppressive phenotype.
CONCLUSION
Our findings support the emerging idea that senescence modifies MSC immunosuppressive properties. Indeed, our results demonstrate a deleterious effect of senescence on MSC capacity to inhibit T-cell mediated immune response, in link with a proteasome-dependent degradation of IDO. Of note, although resting SEN1 MSCs maintain their ability to sustain B-cell proliferation as previously described for SEN2 MSCs [4] , priming by weak inflammatory stimuli was sufficient to convert them into a B-cell suppressive phenotype (Supporting Information Fig. S4 ), suggesting that IDO-independent mechanisms could trigger B-cell inhibition during senescence.
These data encourage the definition of accurate qualification controls of MSCs, in particular focusing on immunosuppressive mechanisms, to optimize their use in the clinic.
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